Short interest for XLMedia gives investors a sense of the degree to which investors are betting on the decline of XLMedia's stock. Short interest data is updated every two weeks.

XLMedia Stock (OTC:XLMDF), Short Interest Report

XLMedia

XLMedia PLC is a digital publishing group that owns and operates websites across a wide variety of industry verticals, including gambling, sports betting, personal finance, and more. It attracts paying users from different online channels and directs them to online gambling operators. The Business's core competency is creating compelling content that attracts engaged audiences and connects them to relevant advertisers. Geographically, it derives a majority of its revenue from North America and also has a presence in Other European countries and the rest of the world.

XLMedia PLC

Loop Capital analyst Rob Sanderson maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and lowers the price target from $555 to $550.

News

Price Target

Analyst Ratings

Loop Capital Maintains Buy on Meta Platforms, Lowers Price Target to $550

Loop Capital analyst Alan Gould maintains Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) with a Hold and raises the price target from $155 to $170.

GOOG

GOOGL

Loop Capital Maintains Hold on Alphabet, Raises Price Target to $170

Loop Capital analyst Chris Dankert maintains Timken (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKR#NYSE">TKR</a>) with a Hold and raises the price target from $78 to $87.

Loop Capital Maintains Hold on Timken, Raises Price Target to $87

WIIM

Boeing shares are trading higher amid overall market strength after Fed Chair Powell said it is unlikely that the next policy rate move would be a rate hike.

Meta shares are trading higher amid overall market strength after Fed Chair Powell said it is unlikely that the next policy rate move would be a rate hike.

Europe ETFs are trading higher amid overall market strength after Fed Chair Powell said it is unlikely that the next policy rate move would be a rate hike.

Legal

Exxon Set To Win FTC Approval For Pioneer Deal With Settlement

JP Morgan analyst John Ivankoe maintains Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Overweight and lowers the price target from $100 to $92.

SBUX

JP Morgan Maintains Overweight on Starbucks, Lowers Price Target to $92

Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) has outperformed the market over the past 15 years by 9.38% on an annualized basis producing an average annual return of 21.53%. Currently, Adobe has a market capitalization of $213.83 billion. 
Buying $100 In ADBE: If an investor had bought $100 of ADBE stock 15 years ago, it would be worth $1,811.40 today based on a price of $477.31 for ADBE at the time of writing.
<h3>Adobe's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714591825_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

ADBE

If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,800 Today

D.R. Horton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) has outperformed the market over the past 15 years by 7.58% on an annualized basis producing an average annual return of 19.73%. Currently, D.R. Horton has a market capitalization of $48.03 billion. 
Buying $1000 In DHI: If an investor had bought $1000 of DHI stock 15 years ago, it would be worth $13,517.15 today based on a price of $145.85 for DHI at the time of writing.
<h3>D.R. Horton's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714591820_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning D.R. Horton Stock In The Last 15 Years

JP Morgan analyst Vivek Juneja maintains Citizens Financial Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFG#NYSE">CFG</a>) with a Neutral and lowers the price target from $36.5 to $36.

JP Morgan Maintains Neutral on Citizens Financial Group, Lowers Price Target to $36

Wednesday,&nbsp;IDEXX Laboratories&nbsp;Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) reported first-quarter adjusted EPS of $2.81, up 10% Y/Y,&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/b38544441/idexx-laboratories-announces-first-quarter-results" rel="noreferrer noopener">beating the consensus of $2.67</a>.
The company reported sales of $964 million, an increase of 7% as reported and organic, missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $966.13 million</a>.
The revenue growth&nbsp;was driven&nbsp;by Companion Animal Group (CAG) growth of 7% as reported and organic, and Water revenue growth of 11% as reported and organic.
IDEXX revenue gains were net of an estimated 0.5% &#8211; 1% negative growth rate impact from severe U.S. weather in January.
The gross margin of 61.5% increased by 120 basis points as reported and ~110 basis points on a comparable basis, supported by benefits from the business mix, lower instrument costs, and&nbsp;improvement in&nbsp;gross margins of software service.
Operating margin was 31.0% for the quarter,&nbsp;10&nbsp;basis points&nbsp;lower than the prior year&#8217;s.
Guidance:&nbsp;IDEXX Laboratories forecasts 2024 revenue of $3.895 billion—$3.965 billion, versus prior guidance of $3.93 billion—$4.04 billion and a consensus of $3.99 billion.
The company expects 2024 CAG Diagnostics Recurring Revenue Growth of 6.5%-8.5% versus prior guidance of 7.5%-10.5%, with organic growth of 7.5%-9.5% compared to&nbsp;prior&nbsp;guidance of 7.5%-10.5%.
The company forecasts 2024 EPS of $10.82-$11.20 versus prior guidance of $10.84-$11.33 and a consensus of $11.12.
William Blair&nbsp;writes that this quarter&#8217;s slower growth&nbsp;was driven&nbsp;by a decline in vet visits and an inclement weather impact in January. Most of these headwinds&nbsp;were expected&nbsp;by investors and already incorporated into guidance.&nbsp;
The analyst writes that Idexx&#8217;s still-solid results demonstrate the durability of the global animal health market and, more specifically, the durability of the company&#8217;s business franchise.
Although current market volume declines are a challenge for short-term growth, William Blair is optimistic about the future due to the increasing number of pet owners from the pandemic-driven surge in puppy adoption.
&#8220;Starting as early as this year and continuing through 2030, we believe an aging pet population will start to require an increasing level of veterinary care (especially diagnostics),&nbsp;and thus presents&nbsp;a solid longer-term tailwind for the industry.&#8221;
William Blair adds, &#8220;Paired with another year of solid pricing growth and the launch of a novel instrument platform (InVue Dx) in later 2024, we also believe the 2025 outlook remains solid.&#8221;
Price Action: IDXX shares are down 3.11% at $477.43 at the last check Wednesday. 
Photo via Pixabay

Analyst Color

Earnings

Guidance

Health Care

Movers

General

IDXX

Aging Pet Population Is 'Solid Longer-Term Tailwind' For IDEXX Labs: Analyst

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) &#8220;could be on its way to becoming a $1 trillion market cap company,&#8221; according to analysts at Cantor Fitzgerald. 
The assessment comes on the heels of an earnings report that shows first-quarter revenue of $8.77 billion. That&#8217;s up 26% year-over-year, just marginally missing the consensus of $8.92 billion.
The Indianapolis-based company saw increases of 16% in volume and 10% in <a href="https://www.benzinga.com/general/biotech/24/04/38521126/eli-lillys-weight-loss-drug-still-going-strong-boosts-annual-forecast" target="_blank" rel="noreferrer noopener">higher realized prices</a>.
Eli Lilly posted an adjusted EPS of $2.58, beating the consensus of $2.46, higher than $1.62 a year ago. Here&#8217;s how analysts reacted:
<ul>
<li>Cantor raised its price target from $815 to $885 with an Overweight rating, driven by earnings revisions. </li>
<li>BofA reiterated the Buy rating with a price target of $1,000.</li>
<li>Truist maintains the Buy rating with a price target increased from $850 to $892.</li>
</ul>
Cantor: Despite the top-line miss that was widely anticipated due to supply constraints, Eli Lilly&#8217;s sales growth of 26% in Q1 2024 is still impressive, the analysts note. The industry average is mid-to-low single digits.
BofA Securities: While earnings beat and forecast raise is expected throughout 2024, the magnitude this early in the year impressed investors, particularly given recent questions on Lilly&#8217;s ability to manufacture enough <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38531968/goldman-scrutinizes-hits-misses-and-growth-trajectory-concerns-for-eli-lilly-and-it" target="_blank" rel="noreferrer noopener">supply for its incretin franchise</a>.
With this backdrop, analysts highlight Lilly&#8217;s unparalleled growth profile and underscoring it&#8217;s a &#8220;have&#8221; in a sea of &#8220;have nots.&#8221; 
Truist: The analyst notes that Mounjaro/Zepbound&#8217;s strong performance drove solid first-quarter revenues, and underlying <a href="https://www.benzinga.com/general/biotech/24/04/38363518/eli-lilly-aims-to-close-supply-demand-gap-for-zepboundmounjaro-as-it-acquires-manufacturing-facil" target="_blank" rel="noreferrer noopener">demand seems healthy</a>.
Truist sees progress made to address manufacturing constraints, which remain at the top of mind given that demand is expected to exceed supply throughout 2024.
Price Action: Eli Lilly shares are down 0.14% at $779.98 at the last check Wednesday.
Read Next: <a href="https://www.benzinga.com/general/biotech/24/04/38291259/eli-lillys-famed-weight-loss-drug-zepbound-works-as-sleep-apnea-treatment-successful-late-stage-s" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s Famed Weight Loss Drug Zepbound Works As Sleep Apnea Treatment, Successful Late-Stage Studies Show</a>.

Biotech

Large Cap

Eli Lilly 'On Its Way' To $1 Trillion Market Cap, Analysts Say: It's A 'Have' In A Sea Of 'Have Nots'

$BTC

Bitcoin is trading lower after the Fed left rates unchanged.

JP Morgan analyst Vivek Juneja maintains Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) with a Overweight and raises the price target from $39.5 to $40.5.

JP Morgan Maintains Overweight on Bank of America, Raises Price Target to $40.5

Hedge Funds

Gundlach Says Base Case Seems Like One Rate Cut This Year, Don't See It Coming In June

Doubleline Capital's Jeffrey Gundlach Says Seems Unlikely That We Will Get 3 Cuts

JP Morgan analyst Vivek Juneja maintains PNC Finl Servs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNC#NYSE">PNC</a>) with a Overweight and lowers the price target from $163.5 to $163.

JP Morgan Maintains Overweight on PNC Finl Servs Gr, Lowers Price Target to $163

JP Morgan analyst Vivek Juneja maintains Truist Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>) with a Neutral and raises the price target from $39.5 to $40.5.

JP Morgan Maintains Neutral on Truist Finl, Raises Price Target to $40.5

ASAN

BBAI

CRWD

MSFT

PLTR

SNOW

SOUN

TWLO

Shares of software stocks are trading higher amid a drop in yields after Fed Chair Powell said it is unlikely that the next policy rate move would be a rate hike.